Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H18O3 |
| Molecular Weight | 294.3444 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=COC2=C1C(=O)C(=O)C3=C2C=CC4=C3CCCC4(C)C
InChI
InChIKey=HYXITZLLTYIPOF-UHFFFAOYSA-N
InChI=1S/C19H18O3/c1-10-9-22-18-12-6-7-13-11(5-4-8-19(13,2)3)15(12)17(21)16(20)14(10)18/h6-7,9H,4-5,8H2,1-3H3
| Molecular Formula | C19H18O3 |
| Molecular Weight | 294.3444 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/15849732Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/27446335
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15849732
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/27446335
Tanshinone IIA is a derivative of phenanthrene-quinone isolated from Danshen, a widely used Chinese herbal medicine. It has antioxidant properties and cytotoxic activity against multiple human cancer cell lines, inducing apoptosis and differentiation of some human cancer cell lines. It was found, that tanshinone IIA might have potential anticancer activity on breast cancers through upregulation and downregulation of multiple genes involved in cell cycle regulation, cell proliferation, apoptosis, signal transduction, transcriptional regulation, angiogenesis, invasive potential and metastatic potential of cancer cells. ADPRTL1 might be the main target at which tanshinone IIA acted. Recently was discovered that tanshinone IIA exerts its cardio protective effects against H2O2-induced cell death by upregulating the expression of Bcl-2 via the activation of the PI3K/Akt signaling pathway, however, further studies are required in order to define and clarify the rationale for its clinical use.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12809358
Curator's Comment: Known to be CNS penetrant in mouse. Human data not available.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: map04151 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27446335 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Preventing | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Tanshinone IIA attenuates epithelial-mesenchymal transition to inhibit the tracheal narrowing. | 2016-11 |
|
| Tanshinone IIA protects H9c2 cells from oxidative stress-induced cell death via microRNA-133 upregulation and Akt activation. | 2016-08 |
|
| Tanshinone IIA decreases the protein expression of EGFR, and IGFR blocking the PI3K/Akt/mTOR pathway in gastric carcinoma AGS cells both in vitro and in vivo. | 2016-08 |
|
| Tanshinone IIA protects cardiac myocytes against oxidative stress-triggered damage and apoptosis. | 2007-07-30 |
|
| Potential anticancer activity of tanshinone IIA against human breast cancer. | 2005-09-20 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15849732
in mice: Seven nude mice bearing human breast s.c. injection of tanshinone IIA at a dose of 30 mg/kg 3 times/week for 10 weeks.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15849732
Tanshinone IIA demonstrated a dose- and time-dependent inhibitory effect on cell growth (IC50 = 0.25 microg/ml), and it significantly inhibited colony formation and BrdU incorporation of human breast cancer cells. Oligonucleotide microarray analysis identified 41 upregulated (1.22%) and 24 downregulated (0.71%) genes after tanshinone IIA treatment
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 22:11:15 GMT 2025
by
admin
on
Mon Mar 31 22:11:15 GMT 2025
|
| Record UNII |
4GPC9FQG6L
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1643339
Created by
admin on Mon Mar 31 22:11:15 GMT 2025 , Edited by admin on Mon Mar 31 22:11:15 GMT 2025
|
PRIMARY | |||
|
686518
Created by
admin on Mon Mar 31 22:11:15 GMT 2025 , Edited by admin on Mon Mar 31 22:11:15 GMT 2025
|
PRIMARY | |||
|
8104
Created by
admin on Mon Mar 31 22:11:15 GMT 2025 , Edited by admin on Mon Mar 31 22:11:15 GMT 2025
|
PRIMARY | |||
|
568-72-9
Created by
admin on Mon Mar 31 22:11:15 GMT 2025 , Edited by admin on Mon Mar 31 22:11:15 GMT 2025
|
PRIMARY | |||
|
DTXSID60205352
Created by
admin on Mon Mar 31 22:11:15 GMT 2025 , Edited by admin on Mon Mar 31 22:11:15 GMT 2025
|
PRIMARY | |||
|
300000040304
Created by
admin on Mon Mar 31 22:11:15 GMT 2025 , Edited by admin on Mon Mar 31 22:11:15 GMT 2025
|
PRIMARY | |||
|
SUB33493
Created by
admin on Mon Mar 31 22:11:15 GMT 2025 , Edited by admin on Mon Mar 31 22:11:15 GMT 2025
|
PRIMARY | |||
|
164676
Created by
admin on Mon Mar 31 22:11:15 GMT 2025 , Edited by admin on Mon Mar 31 22:11:15 GMT 2025
|
PRIMARY | |||
|
4GPC9FQG6L
Created by
admin on Mon Mar 31 22:11:15 GMT 2025 , Edited by admin on Mon Mar 31 22:11:15 GMT 2025
|
PRIMARY | |||
|
686519
Created by
admin on Mon Mar 31 22:11:15 GMT 2025 , Edited by admin on Mon Mar 31 22:11:15 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT |